| abstract |
1. The antibody-drug conjugate compound comprising an antibody covalently linked via a linker to one or more maytanazoid drugs, wherein the compound has the formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein: Ab is an antibody that binds to ErbB receptor or which binds to one or more antigens associated with tumors or cell surface receptors selected from (1) to (36) :( 1) BMPR1B (bone morphogenetic protein receptor and type IB, Genbank accession number NM_001203); (2) E16 (LAT1, SLC7A5, Genbank accession number NM_003486); (3) STEAP1 (sixth transmembrane prostate antigen, Genbank accession number NM_012449); (4) 0772P (CA125, MUC16 , Genbank accession number AF361486); (5) MPF (MPF, MSLN, SMR, megakaryocyte potentiating factor, mesothelin, Genbank accession number NM_005823); (6) Napi3b (NAPI-3B, NPTIIb, SLC34A2, soluble carrier family 34 (sodium phosphate ), representative 2, sodium-dependent phosphate carrier 3b type II, inventory number Genbank NM_006424); (7) Sema 5b (FLJ10372, KIAA1445, Mm.42015, SEMA5B, SEMAG, semaphorin 5b Hlog, sema domain, seven thrombospondins repetitions (type 1 and similar to type 1), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5B, Genbank accession number AB040878) (8) PSCA hlg (2700050C12Rik, C530008016Rik, RIKEN cDNA 2700050C12, RIKEN cDNA gene 2700050C12, gene RIKEN kDNA 2700050C12 Genbank accession number AY358628); (9) ETBR (type B endothelin receptor, Genbank accession number AY275463); (10) MSG783 (RNF124, hypothetical protein FLJ20315, accession number Genbank NM_017763); (11) STEAP2 (HGNC_8639, IPCA, IPCA PCANAP1, STAMP1, STEAP2, STMP, gene 1 associated with prostate cancer, protein 1 associated with prostate cancer, sixth transmembrane epithelial ant |